Page last updated: 2024-10-29

imipramine and Atherogenesis

imipramine has been researched along with Atherogenesis in 1 studies

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ismail, B1
Aboul-Fotouh, S1
Mansour, AA1
Shehata, HH1
Salman, MI1
Ibrahim, EA1
Hassan, OA1
Abdel-tawab, AM1

Other Studies

1 other study available for imipramine and Atherogenesis

ArticleYear
Behavioural, metabolic, and endothelial effects of the TNF-α suppressor thalidomide on rats subjected to chronic mild stress and fed an atherogenic diet.
    Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:5

    Topics: Animals; Antidepressive Agents, Tricyclic; Aorta, Thoracic; Atherosclerosis; Chronic Disease; Depres

2014